Statistics

 array:25 [
  "pii" => "S2254887421001636"
  "issn" => "22548874"
  "doi" => "10.1016/j.rceng.2021.05.008"
  "estado" => "S300"
  "fechaPublicacion" => "2022-03-01"
  "aid" => "1972"
  "copyright" => "The Authors"
  "copyrightAnyo" => "2021"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Rev Clin Esp. 2022;222:131-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0014256521001144"
      "issn" => "00142565"
      "doi" => "10.1016/j.rce.2021.05.004"
      "estado" => "S300"
      "fechaPublicacion" => "2022-03-01"
      "aid" => "1972"
      "copyright" => "The Authors"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "fla"
      "cita" => "Rev Clin Esp. 2022;222:131-7"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Efecto en la vida real sobre el control de los factores de riesgo asociado al inicio con polip&#237;ldora cardiovascular a partir de f&#225;rmacos equipotentes"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "131"
            "paginaFinal" => "137"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0015"
            "etiqueta" => "Figura 3"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr3.jpeg"
                "Alto" => 1566
                "Ancho" => 2508
                "Tamanyo" => 123935
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Cambio en los valores de presi&#243;n arterial &#40;A&#41;&#44; LDLc &#40;B&#41; y descensos en valores absolutos de ambos &#40;C y D&#41; en pacientes que recibieron simult&#225;neamente ambos f&#225;rmacos equipotentes con la polip&#237;ldora-CV antes del cambio&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46; Portela-Romero, S&#46; Cinza-Sanjurjo, P&#46; Conde-Sabar&#237;s, M&#46; Rodr&#237;guez-Ma&#241;ero, P&#46; Maz&#243;n-Ramos, D&#46; Rey-Aldana, J&#46;R&#46; Gonz&#225;lez-Juanatey"
            "autores" => array:7 [
              0 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Portela-Romero"
              ]
              1 => array:2 [
                "nombre" => "S&#46;"
                "apellidos" => "Cinza-Sanjurjo"
              ]
              2 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Conde-Sabar&#237;s"
              ]
              3 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Rodr&#237;guez-Ma&#241;ero"
              ]
              4 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Maz&#243;n-Ramos"
              ]
              5 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Rey-Aldana"
              ]
              6 => array:2 [
                "nombre" => "J&#46;R&#46;"
                "apellidos" => "Gonz&#225;lez-Juanatey"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2254887421001636"
          "doi" => "10.1016/j.rceng.2021.05.008"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887421001636?idApp=WRCEE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256521001144?idApp=WRCEE"
      "url" => "/00142565/0000022200000003/v1_202202260624/S0014256521001144/v1_202202260624/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2254887421001041"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2021.01.003"
    "estado" => "S300"
    "fechaPublicacion" => "2022-03-01"
    "aid" => "1950"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Rev Clin Esp. 2022;222:138-51"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Albuminuria and polyvascular disease improve multivariate predictive models after an acute cardiovascular event&#46; The AIRVAG cohort"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "138"
          "paginaFinal" => "151"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La albuminuria y la enfermedad polivascular mejoran la capacidad predictiva de los modelos multivariados despu&#233;s de un evento cardiovascular agudo&#46; Cohorte AIRVAG"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2321
              "Ancho" => 3175
              "Tamanyo" => 581879
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Kaplan&#8211;Meier survival curves for risk stratification according to usual cutoff points&#46; &#40;A&#41; Framingham&#44; &#40;B&#41; REGICOR&#44; &#40;C&#41; SCORE&#44; &#40;D&#41; SMART&#44; &#40;E&#41; B-TIMI&#44; and &#40;F&#41; REACH&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R&#46; S&#225;ez-Jim&#233;nez, J&#46; Esteban-Hern&#225;ndez, B&#46; Herreros, A&#46; Huelmos, C&#46; Guijarro"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "S&#225;ez-Jim&#233;nez"
            ]
            1 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Esteban-Hern&#225;ndez"
            ]
            2 => array:2 [
              "nombre" => "B&#46;"
              "apellidos" => "Herreros"
            ]
            3 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Huelmos"
            ]
            4 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Guijarro"
            ]
            5 => array:1 [
              "colaborador" => "on behalf of the AIRVAG Investigators"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256521000709"
        "doi" => "10.1016/j.rce.2021.01.008"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256521000709?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887421001041?idApp=WRCEE"
    "url" => "/22548874/0000022200000003/v1_202202260708/S2254887421001041/v1_202202260708/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2254887421001612"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2021.05.007"
    "estado" => "S300"
    "fechaPublicacion" => "2022-03-01"
    "aid" => "1977"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Rev Clin Esp. 2022;222:123-30"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Morbidity and mortality in elderly patients with heart failure managed with a comprehensive care model vs&#46; usual care&#58; The UMIPIC program"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "123"
          "paginaFinal" => "130"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Beneficios de un modelo asistencial integral en pacientes ancianos con insuficiencia card&#237;aca y elevada comorbilidad&#58; programa UMIPIC"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1666
              "Ancho" => 1675
              "Tamanyo" => 117562
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0010"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Evolution of readmissions due to any cause &#40;matched population&#41;&#46;</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">95&#37; CI&#58; 95&#37; confidence interval&#59; RICA&#58; Heart Failure Registry&#59; HR&#58; hazard ratio&#59; UMIPIC&#58; Comprehensive Management Units for Patients with Heart Failure&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "&#193;&#46; Gonz&#225;lez-Franco, J&#46;M&#46; Cerqueiro Gonz&#225;lez, J&#46;C&#46; Ar&#233;valo-Lorido, P&#46; &#193;lvarez-Rocha, S&#46; Carrascosa-Garc&#237;a, A&#46; Armengou, M&#46; Guzm&#225;n-Garc&#237;a, J&#46;C&#46; Trull&#224;s, M&#46; Montero-P&#233;rez-Barquero, L&#46; Manzano"
          "autores" => array:11 [
            0 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Gonz&#225;lez-Franco"
            ]
            1 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Cerqueiro Gonz&#225;lez"
            ]
            2 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Ar&#233;valo-Lorido"
            ]
            3 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "&#193;lvarez-Rocha"
            ]
            4 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Carrascosa-Garc&#237;a"
            ]
            5 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Armengou"
            ]
            6 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Guzm&#225;n-Garc&#237;a"
            ]
            7 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Trull&#224;s"
            ]
            8 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Montero-P&#233;rez-Barquero"
            ]
            9 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Manzano"
            ]
            10 => array:1 [
              "colaborador" => "on behalf of the RICA registry investigators"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S001425652100134X"
        "doi" => "10.1016/j.rce.2021.05.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S001425652100134X?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887421001612?idApp=WRCEE"
    "url" => "/22548874/0000022200000003/v1_202202260708/S2254887421001612/v1_202202260708/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "131"
        "paginaFinal" => "137"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46; Portela-Romero, S&#46; Cinza-Sanjurjo, P&#46; Conde-Sabar&#237;s, M&#46; Rodr&#237;guez-Ma&#241;ero, P&#46; Maz&#243;n-Ramos, D&#46; Rey-Aldana, J&#46;R&#46; Gonz&#225;lez-Juanateyc"
        "autores" => array:7 [
          0 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Portela-Romero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "S&#46;"
            "apellidos" => "Cinza-Sanjurjo"
            "email" => array:1 [
              0 => "scinzas@semergen.es"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Conde-Sabar&#237;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Rodr&#237;guez-Ma&#241;ero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Maz&#243;n-Ramos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Rey-Aldana"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "J&#46;R&#46;"
            "apellidos" => "Gonz&#225;lez-Juanateyc"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "CS Concepci&#243;n Arenal&#44; &#193;rea Sanitaria Integrada Santiago de Compostela&#44; Instituto de Investigaci&#243;n Sanitaria de Santiago de Compostela &#40;IDIS&#41;&#44; Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Cardiovasculares &#40;CIBERCV&#41;&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "CS Porto do Son&#44; &#193;rea Sanitaria Integrada Santiago de Compostela&#44; Instituto de Investigaci&#243;n Sanitaria de Santiago de Compostela &#40;IDIS&#41;&#44; Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Cardiovasculares &#40;CIBERCV&#41;&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Cardiolog&#237;a&#44; Complejo Hospitalario Universitario de Santiago de Compostela&#44; Instituto de Investigaci&#243;n Sanitaria &#40;IDIS&#41;&#44; Universidad de Santiago de Compostela&#44; Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Cardiovasculares &#40;CIBERCV&#41;&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "CS A Estrada&#44; &#193;rea Sanitaria Integrada Santiago de Compostela&#46; Instituto de Investigaci&#243;n Sanitaria de Santiago de Compostela &#40;IDIS&#41;&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Efecto en la vida real sobre el control de los factores de riesgo asociado al inicio con polip&#237;ldora cardiovascular a partir de f&#225;rmacos equipotentes"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1566
            "Ancho" => 2508
            "Tamanyo" => 119801
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Change in blood pressure values &#40;A&#41;&#44; LDLc values &#40;B&#41;&#44; and decreases in the absolute values of both &#40;C and D&#41; in patients who simultaneously received both equally potent drugs with the CV-polypill before the change&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The concept of a polypill arose based on a theoretical estimation which proposed that the combined&#44; simultaneous administration of various drugs indicated for the control of different cardiovascular risk factors &#40;CVRF&#41; could reduce the incidence of cardiovascular &#40;CV&#41; events by 80&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Later clinical trials confirmed the efficacy of a polypill in terms of a decline in low-density lipoprotein cholesterol &#40;LDLc&#41; and blood pressure &#40;BP&#41; in both primary<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> and secondary prevention&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> Recently&#44; the efficacy of adding acetylsalicylic acid &#40;ASA&#41; to a polypill for a reduction of CV events has been demonstrated&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">One of the arguments in favor of a CV-polypill is improved adherence&#46; In this regard&#44; the FOCUS study&#44; <span class="elsevierStyleItalic">Fixed Dose Combination Drug &#40;Polypill&#41; for Secondary Cardiovascular Prevention&#44;</span> &#40;ASA&#44; simvastatin&#44; and ramipril&#59; <span class="elsevierStyleItalic">CNIC-FS-Ferrer</span> polypill&#41;&#44; demonstrated an increase in adherence without observing any significant declines in BP or LDLc&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Another recent pharmacodynamics clinical trial demonstrated that the <span class="elsevierStyleItalic">CNIC-Ferrer</span> CV-polypill with atorvastatin decreased LDLc figures&#44; but not BP figures&#44; due to a possible synergistic effect among the components&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The SORS study&#44; a prospective clinical registry in a population in Mexico&#44;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> found that use of the CV-polypill reduced both LDLc<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> and BP more than treatment with the separate components&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> However&#44; we do not have real-world data that allow for analyzing its impact on said risk factors in a routine clinical practice setting&#44; comparing it to prior treatment with equally potent doses of statins and antihypertensive drugs&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Given the available evidence&#44; we hypothesize that the CV-polypill could be associated with a greater reduction in BP and LDLc figures in patients who previously received treatment with equally potent doses of statins and antihypertensive drugs&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The aim of our study was to analyze the impact of starting treatment with the CNIC-Ferrer CV-polypill on BP and LDLc figures in patients in our healthcare area who previously received equally potent doses of statins and antihypertensive drugs&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients</span><p id="par0030" class="elsevierStylePara elsevierViewall">This work is a retrospective observational analysis of all patients who had an active prescription for the CV-polypill from January 2015 to December 2019 in our healthcare area &#40;Santiago de Compostela&#41; based on the prescription section of our electronic medical record&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">The study protocol was approved by the Drug Research Ethics Committee of Galicia &#40;DREC-G&#41; with registry code 2021&#47;056&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">The variables recorded are listed and defined in <a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> of the supplementary material&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Outcome variable</span><p id="par0045" class="elsevierStylePara elsevierViewall">We analyzed changes in systolic blood pressure &#40;SBP&#41; and diastolic blood pressure &#40;DBP&#41; figures in each visit to the health center and the complete lipid profile &#40;total cholesterol&#44; triglycerides&#44; high-density lipoprotein cholesterol &#40;HDLc&#41; and LDLc&#41; on any blood tests performed&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Any available measurements of both variables in the period from one year before the index date until the end of the observation period were recorded&#46; To express the results&#44; BP or LDLc prior to the use of the CV-polypill were used for comparison&#44; with the last measurement conducted during the previous treatment &#40;<a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> Figure S1 of the supplementary material&#41;&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">The SPSS 22&#46;0 statistical package for Windows was used for data handling and analysis&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">In the descriptive analysis of the sample&#44; the descriptive parameters of the variables were used&#58; mean and standard deviation &#40;SD&#41;&#44; median and interquartile range &#40;P25&#44; P75&#41;&#44; and percentages&#46; The bivariable analysis of the qualitative variables was conducted using the chi-square test&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">To analyze the impact of treatment with the CV-polypill&#44; variations in BP and LDLc figures were analyzed in each patient before and after the treatment&#46; To do so&#44; comparisons were made using Student&#8217;s t test for paired samples&#46; The calculations were conducted for the sample as a whole and for various subgroups who received different equally potent doses of ramipril and atorvastatin according to the antihypertensive and lipid-lowering drugs subjects took previously&#46;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10&#8211;12</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">All results are expressed to the tenths place and no rounding was performed during the calculations&#46; A <span class="elsevierStyleItalic">p</span> value less than &#46;05 was considered statistically significant&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Description of the sample</span><p id="par0075" class="elsevierStylePara elsevierViewall">Data on 547 patients were recorded &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; The mean age was 71&#46;5&#160;&#177;&#160;11&#46;5 years and 60&#46;6&#37; were men&#46; The most prevalent CVRF was HT&#44; 2&#46;1&#37; of patients had prior CV disease&#44; and 19&#46;7&#37; met criteria for chronic kidney disease &#40;CKD&#41;&#46; The median follow-up time for the sample was 55 &#40;15&#44; 118&#41; months&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> Figure S2 of the supplementary material shows the lipid-lowering drugs &#40;A&#41; and antihypertensive drugs &#40;B&#41; prescribed prior to starting the CV-polypill&#46; In addition&#44; 68&#46;5&#37; were in treatment with ASA&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">The CV-polypill was started by primary care physicians in 79&#46;3&#37; of cases&#44; followed by cardiologists &#40;6&#46;2&#37;&#41; and neurologists &#40;2&#46;9&#37;&#41;&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">The mean decline in SBP and DBP and the changes in the lipid profile in the total sample are shown in <a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> Figure S3 of the supplementary material&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Equal potency to ramipril in the CV-polypill</span><p id="par0095" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows the baseline characteristics of the patients in whom each of the doses of ramipril were prescribed to&#46; This drug was mostly prescribed to patients with equally potent doses as the individual component&#58; ramipril 2&#46;5&#160;mg &#40;n&#160;&#61;&#160;84&#59; 48&#46;6&#37;&#41;&#44; ramipril 5&#160;mg &#40;n&#160;&#61;&#160;77&#59; 43&#46;8&#37;&#41;&#44; and ramipril 10&#160;mg &#40;n&#160;&#61;&#160;62&#59; 31&#46;3&#37;&#41;&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">The use of diuretics was similar among the three ramipril dose groups &#40;28&#46;0&#37; vs&#46; 20&#46;7&#37; vs&#46; 27&#46;4&#37;&#44; respectively&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;218&#41;&#44; as was use of beta blockers &#40;32&#46;9&#37; vs&#46; 28&#46;3&#37; vs&#46; 31&#46;3&#37;&#44; respectively&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;341&#41;&#46; Calcium channel blockers were most often used in association with the 10 mg ramipril dose &#40;14&#46;0&#37; vs&#46; 17&#46;0&#37; vs&#46; 30&#46;5&#37;&#44; respectively&#44; <span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41;&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">The start of treatment with ramipril 2&#46;5&#160;mg was associated with significant declines in SBP &#40;<span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41; and DBP &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;004&#41;&#46; The 10 mg dose was also associated with a significant decline in SBP &#40;<span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41;&#46; The declines observed with the 5 mg dose were not statistically significant &#40;<a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> Figure S4 of the supplementary material&#41;&#46; In cases in which the change to ramipril was from other equally potent molecules&#44; a decline of 3&#46;7&#160;mmHg in SBP was observed &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;029&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Equal potency to atorvastatin in the CV-polypill</span><p id="par0110" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows the baseline characteristics of patients according to the dose of atorvastatin in the CV-polypill&#46; It was mostly started in patients treated with statins that were equally potent to atorvastatin 20&#160;mg &#40;n&#160;&#61;&#160;328&#59; 59&#46;4&#37;&#41; and atorvastatin 40&#160;mg &#40;n&#160;&#61;&#160;143&#59; 66&#46;1&#37;&#41;&#46; The start of treatment with the polypill that contained atorvastatin 20&#160;mg or 40&#160;mg was associated with a significant decrease in LDLc &#40;<span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;005 and <span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#44; respectively&#41; &#40;<a class="elsevierStyleCrossRef" href="#sect0140">Appendix A</a> Figure S3 of the supplementary material&#41;&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">In cases in which the statin in the CV-polypill was changed from another equally potent statin&#44; we observed a mean decline in LDLc of 10&#46;6&#160;mg&#47;dL &#40;<span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">In cases in which a change was made simultaneously to equally potent doses of ramipril and atorvastatin &#40;n&#160;&#61;&#160;88&#41;&#44; a decline of 8&#46;7&#160;mg&#47;dL in LDLc was observed &#40;p&#160;&#61;&#160;0&#46;001&#41;&#59; the decline in BP was not statistically significant &#40;<a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#41;&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Discussion</span><p id="par0125" class="elsevierStylePara elsevierViewall">The results of our study show that in routine clinical practice&#44; a significant reduction in LDLc and SBP is observed in patients who start treatment with the CV-polypill compared to previous values under treatment with equally potent doses of statins and antihypertensive drugs&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">Our findings could be justified by greater treatment adherence by substituting the individual components for the CV-polypill and a possible synergistic effect among the polypill&#8217;s components&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5&#8211;7&#44;13&#44;14</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">To our knowledge&#44; this is the first time that efficacy of the CV-polypill in routine clinical practice has been described in terms of lipid and BP control compared to the individual components of equally potent drugs&#46; It could provide additional information to what has been reported in clinical trials or prospective registries&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> We believe that our findings have certain clinical implications for the optimization of cardiovascular risk factor control &#40;LDLc and BP&#41; and secondary prevention in patients with ischemic heart disease&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Various publications have described greater treatment compliance with polypills compared to treatment with individual components&#46; However&#44; the results are not uniform when its efficacy is assessed by means of LDLc and BP control&#46; In the FOCUS study&#44; the greater treatment adherence described was not accompanied by a significant reduction in LDLc or BP levels in the group of patients which received the polypill compared to those treated with individual components&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The authors stated that the lack of better control despite a significant increase in treatment compliance could be due to various reasons&#44; including the characteristics of the clinical trial&#8217;s design with a polypill that included simvastatin&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The SORS study<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> evaluated clinical efficacy &#40;in terms of a reduction in BP and lipids&#41; in a heterogeneous group of patients &#40;secondary prevention and patients with high and moderate cardiovascular risk&#41; who received the CV-polypill in real-world clinical practice in Mexico&#46; In addition to their habitual treatment&#44; patients received a polypill which contained 100&#160;mg of aspirin&#44; 5 or 10&#160;mg of ramipril&#44; and 40&#160;mg of simvastatin for one year&#46; A significant reduction in BP&#44; total cholesterol&#44; and LDLc levels was observed&#44; but no changes were observed in HDLc&#46; In particular&#44; the decrease of 26&#46;3&#160;mg&#47;dL in mean LDLc from a mean of 137&#46;3&#160;mg&#47;dL should be noted&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">The difference observed in our study could be due to the lower baseline LDLc levels in our patients&#44; with an initial level of 102&#46;4&#160;mg&#47;dL among those who were prescribed the 20&#160;mg dose of atorvastatin and 90&#46;5&#160;mg&#47;dL among those treated with 40&#160;mg&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">In our setting&#44; the results of our analysis complement the clinical aspects associated with treatment with the CV-polypill&#44; as they include all patients treated with this strategy in real-world clinical practice conditions in a healthcare area&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Additionally&#44; we evaluated efficacy in terms of a reduction in BP and lipid levels in patients treated with antihypertensive and lipid-lowering drugs with a similar potency to the CV-polypill components&#46; This allowed us to determine their real incremental effect compared to treatment with the individual components&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">As we stated&#44; to our knowledge&#44; this is the first time a study of these characteristics has been conducted&#46; It could strengthen the role of polypills&#44; such as the one studied&#44; in achieving better cardiovascular prevention&#46; The greater efficacy of the CV-polypill in the reduction of BP and LDLc could be related not only to better treatment compliance&#44; but also to a possible synergistic effect of the joint administration of the drugs that it is composed of&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">In a recent clinical study&#44; a greater reduction in BP figures&#44; as measured by outpatient monitoring&#44; and LDLc was observed in a group of patients randomized to receive the CV-polypill compared to those treated with the individual components &#40;ramipril and atorvastatin&#41;&#44; although only the LDLc reduction was statistically significant&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Specifically&#44; an additional 7&#37; reduction in LDLc was observed&#44; similar to what was described when the statin dose was doubled&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">The lack of differences in treatment compliance in patients among the trial&#8217;s three arms ruled out its influence on the results and suggested the possibility of synergies among statins and ACE inhibitors&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Lastly&#44; the high rate of aspirin use in our patients should be mentioned&#44; given that less than 10&#37; had prior CV disease&#46; Low rates of recording cardiovascular disease in the medical records or the decision to provide antiplatelet drugs to patients according to their elevated CV risk could have influenced this finding&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">The recent results of the POLYCAP 3 study with another polypill &#40;simvastatin&#44; atenolol&#44; hydrochlorothiazide&#44; and ramipril&#41; associated with ASA or not in patients with intermediate risk show that combined treatment with aspirin was related to a significant reduction in CV events&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Limitations of the study</span><p id="par0190" class="elsevierStylePara elsevierViewall">This retrospective study analyzes the clinical characteristics included in the comprehensive electronic medical record of patients treated with the CV-polypill in our healthcare area&#46; It has the limitations inherent to this type of design&#44; in which BP measurements and drug prescribing are carried out in a routine clinical practice setting&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">However&#44; we believe that these characteristics may also be a strength&#44; as there are no conditioning factors in the patients&#8217; clinical evaluation&#44; including the measurement of BP figures or the frequency of analytical tests&#46; In addition&#44; evaluating the changes in light of the equal potency of the CV-polypill to previous treatment with the individual components strengthens the hypothesis of a net synergistic effect exerted by the polypill&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">We did not have all variables for all patients&#44; as it was dependent on them being recorded on the medical record&#46; However&#44; the percentage of missing values per variable was 0&#46;07&#37;&#44; a fact that strengthens the validity of our findings&#46; Along these lines&#44; the availability of information such as adjuvant treatments and the evolution of BP measurements and LDLc analyses are sufficiently abundant for analyzing the evolution of the main variables and controlling for the effect of confounding factors&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">We are aware that assuming the equal potency of antihypertensive drugs and statins with ramipril and atorvastatin in the CV-polypill has certain limitations&#59; however&#44; they are those recommended by clinical practice guidelines and reference meta-analyses&#46;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10&#8211;12</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">Finally&#44; we do not know the indication of the CV-polypill and we were not able to evaluate patients&#8217; treatment compliance either during the period in which they were treated with the individual components or with the CV-polypill&#44; which are aspects that could influence our results&#46;</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conclusions</span><p id="par0215" class="elsevierStylePara elsevierViewall">Initiating treatment with the CV-polypill was associated with a significant decline in LDLc and BP figures&#46; Among patients who had previously received equally potent treatment with statins and antihypertensive drugs&#44; starting the CV-polypill was associated with a considerable decline in LDLc&#44; but the decline was not statistically significant in the case of SBP&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">As we have described&#44; our findings suggest that in a routine clinical practice scenario&#44; the observations of clinical trials and prospective registries which indicate that these effects could be associated with better treatment compliance and a possible synergistic effect among the drugs&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Funding</span><p id="par0225" class="elsevierStylePara elsevierViewall">The authors have not received any funding for the conduct of this study&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflicts of interest</span><p id="par0230" class="elsevierStylePara elsevierViewall">The authors declare no conflicts of interest in regard to this article&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1672378"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Objective"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Material and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1484325"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1672379"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Objetivo"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Material y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1484324"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Materials and methods"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Patients"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Outcome variable"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0030"
          "titulo" => "Results"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Description of the sample"
            ]
            1 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Equal potency to ramipril in the CV-polypill"
            ]
            2 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Equal potency to atorvastatin in the CV-polypill"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0050"
          "titulo" => "Discussion"
          "secciones" => array:1 [
            0 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Limitations of the study"
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conclusions"
        ]
        9 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Funding"
        ]
        10 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conflicts of interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2021-03-21"
    "fechaAceptado" => "2021-05-13"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1484325"
          "palabras" => array:5 [
            0 => "Dyslipidemia"
            1 => "Hypertension"
            2 => "Cardiovascular risk"
            3 => "Polypill"
            4 => "Equivalent potency"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1484324"
          "palabras" => array:5 [
            0 => "Dislipemia"
            1 => "Hipertensi&#243;n arterial"
            2 => "Riesgo cardiovascular"
            3 => "Polip&#237;ldora"
            4 => "Equipotencia"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">This work aims to analyze the impact of Spain&#8217;s National Center for Cardiovascular Research &#40;CNIC-Ferrer&#41;&#8217;s cardiovascular &#40;CV&#41;-polypill on blood pressure &#40;BP&#41; and low-density lipoprotein cholesterol &#40;cLDL&#41; levels in patients in our healthcare area who previously took equipotent doses of statins and antihypertensives&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and methods</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">All patients in our healthcare area &#40;Santiago de Compostela&#44; Spain&#41; who&#44; as of December 31&#44; 2019&#44; had an active prescription for the CV-polypill &#40;CNIC-Ferrer&#41; since January 16&#44; 2015 were registered&#46; The index date was the start date of the CV-polypill prescription&#46; The drugs the patient had previously received for dyslipidemia and hypertension were analyzed&#44; classifying them by their equivalent potency to atorvastatin and ramipril&#46; Changes in cLDL and BP were analyzed by means of Student&#8217;s t-test for paired samples&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">We analyzed 547 patients with a mean age of 71&#46;5&#160;&#177;&#160;11&#46;5 years&#46; The majority were men &#40;60&#46;6&#37;&#41;&#46; We observed a decrease in cLDL &#40;&#8722;10&#46;6 &#91;95&#37; CI&#58; &#8722;7&#46;0&#44; &#8722;14&#46;3&#93;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#60;&#160;0&#46;001&#41; in patients who started taking the CV-polypill who had previously taken equally potent doses of atorvastatin &#40;n&#160;&#61;&#160;471&#41;&#46; We documented a reduction in systolic BP &#40;&#8722;3&#46;7 &#91;95&#37; CI&#58; &#8722;0&#46;4&#44; &#8722;6&#46;9&#93;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;029&#41; in patients who had previously taken equally potent doses of ramipril &#40;n&#160;&#61;&#160;360&#41;&#46; In 88 patients&#44; the CV-polypill was started via equally potent doses of atorvastatin and ramipril&#44; with a decrease in cLDL &#40;&#8722;8&#46;7 &#91;95&#37; CI&#58; &#8722;3&#46;8&#44; &#8722;13&#46;6&#93;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;001&#41; and systolic BP &#40;&#8722;3&#46;6 &#91;95&#37; CI&#58; &#8722;7&#46;8&#44; 0&#46;5&#93;&#44; <span class="elsevierStyleItalic">p</span>&#160;&#61;&#160;0&#46;085&#41;&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">The initiation of treatment with the CV-polypill in patients who previously received equally potent treatment with atorvastatin and ramipril was associated with a greater reduction in cLDL and systolic BP&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Material and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Analizar el impacto del inicio del tratamiento con la polip&#237;ldora-cardiovascular &#40;CV&#41; del Centro Nacional de Investigaciones Cardiovasculares &#40;CNIC-Ferrer&#41;&#44; en las cifras de presi&#243;n arterial &#40;PA&#41; y colesterol ligado a lipoprote&#237;nas de baja densidad &#40;LDL&#41;&#44; de los pacientes de nuestra &#225;rea sanitaria que previamente recib&#237;an dosis equipotentes de estatinas y antihipertensivos&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y m&#233;todos</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Se registraron todos los pacientes de nuestra &#225;rea sanitaria &#40;Santiago de Compostela&#41; que a 31 de diciembre de 2019 ten&#237;an una prescripci&#243;n activa de polip&#237;ldora-CV &#40;CNIC-Ferrer&#41;&#44; desde el 16 de enero de 2015&#46; La fecha &#237;ndice fue la fecha de inicio de prescripci&#243;n de polip&#237;ldora-CV&#44; y se analizaron los f&#225;rmacos que previamente recib&#237;a el paciente para dislipemia e hipertensi&#243;n arterial&#44; clasific&#225;ndose por equipotencias con atorvastatina y ramipril&#46; Se analiz&#243; mediante la prueba t-Student para muestras apareadas las variaciones de colesterol LDL y PA&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Analizamos 547 pacientes con una edad media de 71&#44;5&#160;&#177;&#160;11&#44;5 a&#241;os y la mayor&#237;a varones &#40;60&#44;6&#37;&#41;&#46; Observamos un descenso del colesterol LDL &#40;&#8722;10&#44;6 &#91;IC95&#37;&#58; &#8722;7&#44;0&#44; &#8722;14&#44;3&#93;&#44; p&#160;&#60;&#160;0&#44;001&#41; en los pacientes &#40;n&#160;&#61;&#160;471&#41; que iniciaron la polip&#237;ldora-CV con dosis previas equipotentes de atorvastatina&#46; Documentamos una reducci&#243;n de la PA sist&#243;lica &#40;&#8722;3&#44;7 &#91;IC95&#37;&#58; &#8722;0&#44;4&#44; &#8722;6&#44;9&#93;&#44; p&#160;&#61;&#160;0&#44;029&#41; en los pacientes &#40;n&#160;&#61;&#160;360&#41; con inicio a partir de dosis equipotentes de ramipril&#46; En 88 pacientes&#44; el inicio de la polip&#237;ldora-CV se hizo a partir de dosis equipotentes de atorvastatina y ramipril observ&#225;ndose un descenso del colesterol LDL &#40;&#8722;8&#44;7 &#91;IC95&#37;&#58; &#8722;3&#44;8&#44; &#8722;13&#44;6&#93;&#44; p&#160;&#61;&#160;0&#44;001&#41; y de la PA sist&#243;lica &#40;&#8722;3&#44;6 &#91;IC95&#37;&#58; &#8722;7&#44;8&#44; 0&#44;5&#93;&#44; p&#160;&#61;&#160;0&#44;085&#41;&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">El inicio del tratamiento con la polip&#237;ldora-CV&#44; en pacientes que previamente recib&#237;an tratamientos equipotentes de atorvastatina y ramipril&#44; se asoci&#243; a una mayor reducci&#243;n del colesterol LDL y la PA sist&#243;lica&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Material y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Portela-Romero M&#44; Cinza-Sanjurjo S&#44; Conde-Sabar&#237;s P&#44; Rodr&#237;guez-Ma&#241;ero M&#44; Maz&#243;n-Ramos P&#44; Rey-Aldana D&#44; et al&#46; Efecto en la vida real sobre el control de los factores de riesgo asociado al inicio con polip&#237;ldora cardiovascular a partir de f&#225;rmacos equipotentes&#46; Rev Clin Esp&#46; 2022&#59;222&#58;131&#8211;137&#46;</p>"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0240" class="elsevierStylePara elsevierViewall">The following are Supplementary data to this article&#58;<elsevierMultimedia ident="upi0005"></elsevierMultimedia><elsevierMultimedia ident="upi0010"></elsevierMultimedia><elsevierMultimedia ident="upi0015"></elsevierMultimedia><elsevierMultimedia ident="upi0020"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Supplementary data"
            "identificador" => "sec0080"
          ]
        ]
      ]
    ]
    "multimedia" => array:8 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 757
            "Ancho" => 2508
            "Tamanyo" => 86628
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Change in blood pressure values &#40;A&#41; and decreases in absolute values &#40;B&#41; in patients who took antihypertensive drugs that were equally potent to ramipril with the CV-polypill before the change&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 920
            "Ancho" => 2508
            "Tamanyo" => 69923
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Change in LDLc values &#40;A&#41; and decreases in absolute values &#40;B&#41; in patients who took drugs that were equally potent to atorvastatin in the CV-polypill before the change&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1566
            "Ancho" => 2508
            "Tamanyo" => 119801
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Change in blood pressure values &#40;A&#41;&#44; LDLc values &#40;B&#41;&#44; and decreases in the absolute values of both &#40;C and D&#41; in patients who simultaneously received both equally potent drugs with the CV-polypill before the change&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Quantitative variables are shown as mean&#160;&#177;&#160;SD&#46; Qualitative variables are shown as total number of patients &#40;n&#41; and percentage of the total sample&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">AT&#58; atorvastatin&#59; BMI&#58; body mass index&#59; CV disease&#58; cardiovascular disease&#59; DBP&#58; diastolic blood pressure&#59; DM&#58; diabetes mellitus&#59; HDL&#58; high-density lipoprotein cholesterol&#59; HT&#58; hypertension&#59; LDL cholesterol&#58; low-density lipoprotein cholesterol&#59; SBP&#58; systolic blood pressure&#59; SD&#58; standard deviation&#59; RAM&#58; ramipril&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_colgroup " colspan="7" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">According to the CV-polypill composition</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Total&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">AT 20&#160;mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">AT 40&#160;mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col"><span class="elsevierStyleItalic">p</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">RAM 2&#46;5&#160;mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">RAM 5&#160;mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">RAM 10&#160;mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col"><span class="elsevierStyleItalic">p</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;547&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;379&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;168&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;173&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;176&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#40;n&#160;&#61;&#160;198&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sex &#40;female&#41;&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">218 &#40;39&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">166 &#40;44&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50 &#40;29&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;002&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52 &#40;30&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67 &#40;38&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">98 &#40;49&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Age &#40;years&#41;&#44; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71&#46;5&#160;&#177;&#160;11&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72&#46;5&#160;&#177;&#160;11&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">69&#46;3&#160;&#177;&#160;11&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;004&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">70&#46;6&#160;&#177;&#160;13&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71&#46;8&#160;&#177;&#160;10&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72&#46;2&#160;&#177;&#160;10&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;373&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Family history of CV disease&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;5&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;3&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;9&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;5&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;4&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;5&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;962&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Obesity&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">225 &#40;41&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;3&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;9&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63 &#40;36&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75 &#40;42&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">90 &#40;45&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;223&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hypercholesterolemia&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">473 &#40;86&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">163 &#40;42&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">65 &#40;38&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;378&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">144 &#40;83&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">159 &#40;90&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">169 &#40;85&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;139&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hypertension&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">485 &#40;88&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">334 &#40;88&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">138 &#40;82&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;067&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">136 &#40;78&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">162 &#40;92&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">186 &#40;93&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diabetes mellitus&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">229 &#40;41&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">162 &#40;42&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67 &#40;39&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;531&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68 &#40;39&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;42&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87 &#40;43&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;664&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Prior CV disease&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;2&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;2&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;1&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;796&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;2&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;2&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;540&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Heart failure&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42 &#40;7&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">163 &#40;42&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67 &#40;39&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;505&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68 &#40;39&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;42&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87 &#40;43&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;664&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Chronic kidney disease&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">108 &#40;19&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;7&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;7&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;998&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;6&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;9&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;6&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;483&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Atrial fibrillation&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;2&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75 &#40;19&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33 &#40;19&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;980&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49 &#40;28&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;17&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;002&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BMI &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#59; mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;6&#160;&#177;&#160;5&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;7&#160;&#177;&#160;5&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;2&#160;&#177;&#160;4&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;311&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;2&#160;&#177;&#160;5&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;4&#160;&#177;&#160;4&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;9&#160;&#177;&#160;5&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;546&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SBP &#40;mmHg&#41; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">142&#46;7&#160;&#177;&#160;18&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">144&#46;9&#160;&#177;&#160;18&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">137&#46;4&#160;&#177;&#160;17&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">140&#46;8&#160;&#177;&#160;19&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">142&#160;&#177;&#160;17&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">144&#46;7&#160;&#177;&#160;17&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;172&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">DBP &#40;mmHg&#41; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&#46;2&#160;&#177;&#160;12&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&#46;4&#160;&#177;&#160;11&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">76&#46;3&#160;&#177;&#160;12&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;7&#160;&#177;&#160;12&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&#46;0&#160;&#177;&#160;12&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&#46;4&#160;&#177;&#160;11&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;164&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Total cholesterol &#40;mg&#47;dL&#41;&#44; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">176&#46;1&#160;&#177;&#160;80&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">182&#46;2&#160;&#177;&#160;93&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">163&#46;2&#160;&#177;&#160;38&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">173&#46;9&#160;&#177;&#160;49&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">171&#46;9&#160;&#177;&#160;43&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">182&#46;0&#160;&#177;&#160;119&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;446&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Triglycerides &#40;mg&#47;dL&#41;&#44; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">131&#46;9&#160;&#177;&#160;73&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">128&#46;3&#160;&#177;&#160;73&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">140&#46;4&#160;&#177;&#160;74&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;081&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">135&#46;6&#160;&#177;&#160;83&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">135&#46;9&#160;&#177;&#160;75&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">124&#46;9&#160;&#177;&#160;61&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;269&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HDL cholesterol &#40;mg&#47;dL&#41;&#44; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&#46;2&#160;&#177;&#160;16&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;0&#160;&#177;&#160;18&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&#46;3&#160;&#177;&#160;12&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&#46;2&#160;&#177;&#160;14&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&#160;&#177;&#160;15&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&#46;2&#160;&#177;&#160;19&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;532&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LDL cholesterol &#40;mg&#47;dL&#41;&#44; &#40;mean&#160;&#177;&#160;SD&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">98&#46;8&#160;&#177;&#160;35&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">102&#46;7&#160;&#177;&#160;37&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">90&#46;48&#160;&#177;&#160;31&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;0&#46;001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">99&#46;4&#160;&#177;&#160;40&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">96&#46;3&#160;&#177;&#160;33&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#46;6&#160;&#177;&#160;33&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;528&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2845751.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics in all patients and according to the CV-polypill composition&#46;</p>"
        ]
      ]
      4 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.pdf"
          "ficheroTamanyo" => 161971
        ]
      ]
      5 => array:5 [
        "identificador" => "upi0010"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc2.pdf"
          "ficheroTamanyo" => 813577
        ]
      ]
      6 => array:5 [
        "identificador" => "upi0015"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc3.pdf"
          "ficheroTamanyo" => 122503
        ]
      ]
      7 => array:5 [
        "identificador" => "upi0020"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc4.pdf"
          "ficheroTamanyo" => 156611
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:14 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A strategy to reduce cardiovascular disease by more than 80&#37;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "N&#46;J&#46; Wald"
                            1 => "M&#46;P&#46; Law"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/bmj.326.7404.1419"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMJ"
                        "fecha" => "2003"
                        "volumen" => "326"
                        "paginaInicial" => "1419"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12829553"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of a polypill &#40;Polycap&#41; on risk factors in middle-aged individuals without cardiovascular disease &#40;TIPS&#41;&#58; a phase II&#44; double-blind&#44; randomised trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Yusuf"
                            1 => "P&#46; Pais"
                            2 => "R&#46; Afzal"
                            3 => "D&#46; Xavier"
                            4 => "K&#46; Teo"
                            5 => "J&#46; Eikelboom"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(09)60611-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2009"
                        "volumen" => "373"
                        "paginaInicial" => "1341"
                        "paginaFinal" => "1351"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19339045"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk for CVD&#46; The UMPIRE randomized clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Thom"
                            1 => "N&#46; Poulter"
                            2 => "J&#46; Field"
                            3 => "A&#46; Patel"
                            4 => "D&#46; Prabhakaran"
                            5 => "A&#46; Stanton"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2013"
                        "volumen" => "310"
                        "paginaInicial" => "918"
                        "paginaFinal" => "929"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Polypill with or without aspirin in persons without cardiovascular disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Yusuf"
                            1 => "P&#46; Joseph"
                            2 => "A&#46; Dans"
                            3 => "P&#46; Gao"
                            4 => "K&#46; Teo"
                            5 => "D&#46; Xavier"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa2028220"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "384"
                        "paginaInicial" => "216"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33186492"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A polypill strategy to improve adherence&#46; Results from the FOCUS projects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Castellano"
                            1 => "G&#46; Sanz"
                            2 => "J&#46;L&#46; Pe&#241;alvo"
                            3 => "S&#46; Bansilal"
                            4 => "A&#46; Fern&#225;ndez-Ortiz"
                            5 => "L&#46; &#193;lvarez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2014.08.021"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2014"
                        "volumen" => "64"
                        "paginaInicial" => "2071"
                        "paginaFinal" => "2082"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25193393"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacodynamic study of the cardiovascular polypill&#46; Is there any interaction among the monocomponents&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;R&#46; Gonz&#225;lez-Juanatey"
                            1 => "J&#46; Tamargo"
                            2 => "F&#46; Torres"
                            3 => "B&#46; Weisser"
                            4 => "N&#46; Oudovenko"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rec.2019.11.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Esp Cardiol"
                        "fecha" => "2021"
                        "volumen" => "74"
                        "paginaInicial" => "51"
                        "paginaFinal" => "58"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31983653"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical effectiveness of the cardiovascular polypill in a real-life setting in patients with cardiovascular risk&#58; the SORS study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Castellano"
                            1 => "J&#46; Verdejo"
                            2 => "S&#46; Ocampo"
                            3 => "M&#46;M&#46; Rios"
                            4 => "E&#46; G&#243;mez-&#193;lvarez"
                            5 => "G&#46; Borrayo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.arcmed.2019.04.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Med Res"
                        "fecha" => "2019"
                        "volumen" => "50"
                        "paginaInicial" => "31"
                        "paginaFinal" => "40"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31101241"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease&#58; results from a real-world setting in Mexico"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46; G&#243;mez-&#193;lvarez"
                            1 => "J&#46; Verdejo"
                            2 => "S&#46; Ocampo"
                            3 => "C&#46;I&#46; Ponte-Negretti"
                            4 => "E&#46; Ru&#237;z"
                            5 => "M&#46;M&#46; R&#237;os"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "IJC Hear Vasc"
                        "fecha" => "2020"
                        "volumen" => "29"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico&#58; a post hoc analysis of the SORS study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; G&#243;mez-&#193;lvarez"
                            1 => "J&#46; Verdejo"
                            2 => "S&#46; Ocampo"
                            3 => "E&#46; Ruiz"
                            4 => "M&#46;A&#46; Martinez-Rios"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/fca-2019-0075"
                      "Revista" => array:6 [
                        "tituloSerie" => "Future Cardiol"
                        "fecha" => "2020"
                        "volumen" => "16"
                        "paginaInicial" => "53"
                        "paginaFinal" => "60"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31850802"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systematic review&#58; comparative effectiveness of angiotensin- converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;B&#46; Matchar"
                            1 => "D&#46;C&#46; McCrory"
                            2 => "L&#46;A&#46; Orlando"
                            3 => "M&#46;R&#46; Patel"
                            4 => "U&#46;D&#46; Patel"
                            5 => "M&#46;B&#46; Patwardhan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7326/0003-4819-148-1-200801010-00189"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "2008"
                        "volumen" => "148"
                        "paginaInicial" => "16"
                        "paginaFinal" => "29"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17984484"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Telmisartan&#44; Ramipril&#44; or both in patients at high risk for vascular events"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "The ONTARGET investigators"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0801317"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "1547"
                        "paginaFinal" => "1559"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18378520"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2016 European Guidelines on cardiovascular disease prevention in clinical practice&#58; the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice &#40;constituted by representatives of 10 societies and by invited experts&#41; Developed with the special contribution of the European Association for Cardiovascular Prevention &#38; Rehabilitation &#40;EACPR&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;F&#46; Piepoli"
                            1 => "A&#46;W&#46; Hoes"
                            2 => "S&#46; Agewall"
                            3 => "C&#46; Albus"
                            4 => "C&#46; Brotons"
                            5 => "A&#46;L&#46; Catapano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2315"
                        "paginaFinal" => "2381"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Strengths and Limitations of using the polypill in cardiovascular prevention"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Roy"
                            1 => "N&#46; Naik"
                            2 => "K&#46; Srinath Reddy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11886-017-0853-y"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Cardiol Rep"
                        "fecha" => "2017"
                        "volumen" => "19"
                        "paginaInicial" => "45"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28425033"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The polypill&#58; an effective approach to increasing adherence and reducing cardiovascular event risk"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P&#46; Bramlage"
                            1 => "H&#46; Sims"
                            2 => "J&#46; Minguet"
                            3 => "C&#46; Ferrero"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/2047487316674817"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Prev Cardiol"
                        "fecha" => "2017"
                        "volumen" => "24"
                        "paginaInicial" => "297"
                        "paginaFinal" => "310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27798363"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22548874/0000022200000003/v1_202202260708/S2254887421001636/v1_202202260708/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "1901"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22548874/0000022200000003/v1_202202260708/S2254887421001636/v1_202202260708/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887421001636?idApp=WRCEE"
]